Korean Skin Botox: What Intradermal Toxin Can and Cannot Do

Ask ten injectors what "skin botox" is and you will get ten answers. Some mean a few extra units into the crow's feet. Some mean a hyperdiluted toxin spread across the whole face. Some mean a cocktail where toxin is mixed into a skin booster syringe. In Korea we have been doing intradermal toxin for long enough that the word has become a menu item, and that is exactly the problem. When a technique becomes a menu item, people stop asking what it actually does.

So this article is not a sales page for skin botox. It is the conversation I would have with you chairside: what the mechanism supports, where it is placed, how to keep the dose knowable, and who should not have it.

In Korean aesthetic clinics, this approach is also known as dermotoxin. Its wider uptake sits within a broader expansion of toxin treatment: Korea's first domestically developed type A toxin was approved in 2006, and competition among local manufacturers subsequently helped lower treatment costs.

What "skin botox" actually is

Skin botox (also called microbotox or intradermal toxin) is botulinum toxin type A placed in the dermis instead of the muscle. The molecular action is the same as anywhere else: the toxin cleaves SNAP-25 and blocks acetylcholine release. What changes is the target.

Some facial muscle fibres attach to the skin. Relaxing those superficial fibres is one proposed contributor to softer fine expression lines. The aim is to reduce their pull on the skin while preserving broader facial movement, although unwanted muscle weakness can still occur if toxin spreads.

The smoother appearance need not have a single explanation. Sweat suppression is established, and reduced oiliness has been reported at some sites, but the mechanism of sebum reduction remains under study. These observations do not establish that toxin directly contracts sebaceous glands or pores; the evidence for pore-size improvement is less certain.

Intradermal is the only route I consider defensible. Topical toxin does not work: the molecule is around 150 kDa, far above what intact skin lets through, and topical toxin failed in Phase 3. Spreading toxin onto a microneedled or lasered skin bed is not a delivery method either. If you want toxin in the dermis, you put it there with a needle.

A regulatory note for colleagues in the US: intradermal toxin for skin quality is an off-label use of an approved product. That belongs in your consent form, by name.

What the evidence supports — and what it doesn't

This is where I want you to be stricter than the marketing. In our Skinboosters Fact Sheet I grade each claim, and the grades are not all equal.

• EstablishedSweat suppressionEccrine sweat is the one proven cutaneous target.
• PlausibleSebum reduction — at specific sitesRandomised data exist for the forehead and scalp, with effects reported over roughly three to six months. The mechanism is still not proven.
• PlausibleTexture and fine-line smoothingConsistently reported, weakly controlled.
• ConfoundedPore-size reductionIn controlled work, the saline side improved as well. Much of what we call a "pore effect" is probably the needling itself.
• Not supported"Tightening" through the arrector piliThose fibres are adrenergic, not cholinergic. Toxin has no business there, and we took that claim out of our Fact Sheet.

What does this mean in front of a patient? If someone comes in for oily forehead skin or fine crepey texture, skin botox is a reasonable conversation. If someone comes in because a feed told them it shrinks pores, I tell them honestly that the evidence for that is weak, and that we may be paying for the needle, not the toxin.

Dilution: keep the units knowable

Every dilution conversation should start with one question: can you state the units actually delivered at each site? If you cannot, the dilution is wrong, or the mixing is. I say it to trainees as units, not syringes.

The concept is simple. Concentration is vial units divided by total volume, and units per site are concentration times the aliquot you place. For standalone skin botox, the working approach in our Fact Sheet is a further dilution of the standard reconstitution. For example, a 100 U vial reconstituted in 2.5 mL and then diluted 1:1 to 5 mL gives 20 U/mL. When toxin goes into a booster session instead, it stays at the standard concentration so that the smallest possible volume is added. The full quick-reference table, including the full-vial dilutions that are for standalone use only, is in the Skinboosters Fact Sheet.

Two fixed points regardless of the scheme: dilute with preservative-free 0.9% sodium chloride, which is what current US labels for type A toxins specify; and remember that toxin units are product-specific. A unit of one brand is not a unit of another, so never carry a dilution from one product to a different one without checking its label. And syringe capacity is not potency: insulin-scale markings are not toxin units. I read volume in millilitres and calculate the units from it, every time.

For total dose per session, the Skinboosters Fact Sheet lists 50–100 U for standalone skin botox and 20–40 U when used with boosters. These are the ranges described in that protocol, not universal doses across toxin brands. Units are product-specific, so the product, treatment area and individual patient must be considered rather than transferring these numbers directly to another formulation. In a booster session, the booster and toxin are preferably injected sequentially.

Before the needle

Skin botox is many small punctures across the face, so preparation is not a formality. I start with a full cleanse. It removes makeup and debris so I can see the real condition of the skin, and it is the first step against infection. Then I choose the antiseptic knowingly: an alcohol swab is fast but can dry and irritate; diluted povidone-iodine covers broadly but stains and is out for iodine allergy; diluted chlorhexidine is gentle and long-lasting but must be kept away from the eyes and ears.

Comfort matters too. A patient who leaves with a sore, bruised face does not come back for the second session, and skin quality is built over sessions. Topical anaesthesia given enough time, and attention to each patient's pain threshold, is part of the technique.

Depth and pattern

The goal is shallow, even placement that raises a tiny bleb without leakage. My reference is a 34 G needle (2 or 4 mm) at about 15 degrees, with injections at 1 cm intervals, and I confirm depth by the bleb, not by feel. A microneedle injector with negative suction is an alternative. How much leakage is acceptable depends on the viscosity of what you are injecting.

The same logic shows up in conventional toxin work. In the crow's feet, the Toxin Fact Sheet places injections superficially intradermal, just enough to raise a small wheal, with the needle directed away from the orbit. Superficial placement is not a separate world from muscle toxin; it is a depth decision you already make.

Facial zones: treatment fields and caution areas

Treatment planning may include the forehead and glabellar skin, lateral crow's feet, and the T-zone and medial cheeks, depending on the patient's concern. The jawline and neck are also considered in selected patients, where the superficial platysma is part of the treatment rationale. These are treatment fields, not a promise of equal benefit at every site; the evidence grades above still apply.

The lower and mid-cheek, the zygomatic region and the area around the mouth need particular caution because nearby smile and lip muscles may be affected. Unwanted weakness can change the smile, create asymmetry or impair lip function. The infraorbital area, especially medially, also requires a separate assessment of lower-lid support and ocular symptoms; treatment near the orbicularis oculi can affect blinking and tear function. I would not present the under-eye region as a routine low-risk treatment field.

In the skin-botox approach described here, the upper eyelid itself and the lip vermilion and border are excluded. This is the boundary of this protocol, rather than a statement that toxin is contraindicated at those sites for every other indication. Superficial placement reduces neither spread nor weakness risk to zero: it does not guarantee preservation of brow position, eyelid function or the smile.

Mixing rules: sequential beats mixed

Most of the trouble with skin botox comes from the cocktail syringe. Our Fact Sheet keeps it to four rules:

1. Sequential beats mixed. Inject the booster and the toxin as two products in one session, so the dose per site stays known.
2. Mixing has no validation. There is no potency, stability or compatibility assay for type A toxin mixed with HA, PN/PDRN, PRP or exosome. "Compatible" means customary, not tested.
3. Every transfer costs potency. Syringe-to-syringe transfer alone has been measured at around 42% loss, and HA transfer causes phase separation.
4. Never mix toxin with PRP or PRF. Plasma alpha-macroglobulins reduce toxin activity. Inject them separately.

One more reason to counsel carefully: in a split-face study of HA with microdroplet toxin given sequentially, palpable lumps were reported on more than half of the combination sides. That figure belongs to that study and that product, but it is a number your patient should hear before a combination session.

Safety and patient selection

Before any toxin, intradermal or not, I go through the same checklist: active infection or inflammation at the site, known hypersensitivity, pregnancy or breastfeeding, and neuromuscular disease such as myasthenia gravis, Lambert-Eaton syndrome or ALS. I also screen for unrealistic expectations. A patient who wants a filter result from a toxin is not a skin botox candidate.

Good candidates are the ones whose concern matches what the evidence supports: sweat, oil at the forehead or scalp, and fine texture. Where texture and fine lines are the main issue, we often pair an HA skin booster with a separate intradermal toxin pass in the same session and repeat every three to six months.

Onset, duration and repeat treatment

For standalone skin botox, the counselling window I use is an initial change at around 3–5 days, with the fuller response assessed at 1–2 weeks. The perceived skin-quality effect often lasts around 2–3 months, with variation between patients, treatment sites and the particular concern being assessed. These are clinical expectations, not a guarantee that every effect begins, peaks or wears off on the same schedule.

For this standalone protocol, I generally plan repeat treatment at 3–4 months, after reassessment, rather than routine short-interval top-ups. The two-week review is a check on response and adverse effects, not an automatic repeat injection. The product's labelling and the patient's total toxin exposure across treatment areas also matter.

Avoiding unnecessary frequent injections is part of planning repeated toxin treatment, but waiting three months does not guarantee prevention of neutralising antibodies. A formulation without complexing proteins should not be described as resistance-proof, and a shorter visible effect should not automatically be attributed to faster metabolism or absorption after intradermal placement.

Expected recovery and warning symptoms

Small raised wheals at the injection points are expected after intradermal placement. In the counselling guide used here, they usually settle within hours to 24 hours, occasionally taking 1–2 days. Bruising, mild swelling and needle marks may take several days to two weeks to fade. A mild headache or local soreness may last 1–3 days, and some patients notice dryness or tightness during the first 1–2 weeks; gentle moisturising may help. These are expected recovery windows, not a reason to ignore symptoms that persist or worsen.

Patients should distinguish a routine recovery question from a problem that needs immediate assessment:

• Emergency care: breathing, swallowing or speech difficulty; swelling of the tongue or throat; or hives accompanied by breathing difficulty, marked dizziness or collapse. Seek emergency help rather than waiting for the treating clinic to respond. For clinicians, suspected anaphylaxis requires prompt intramuscular epinephrine and emergency assistance; antihistamines and corticosteroids must not replace or delay epinephrine.
• Immediate medical assessment: new generalised weakness or double vision after toxin treatment, including symptoms arising hours to weeks later. Any accompanying breathing or swallowing difficulty is an emergency.
• Urgent contact and examination: worsening pain, spreading redness or heat, discharge or pus, or fever and chills. Do not wait for a particular day after treatment before reporting these signs. Persistent blanching or mottled skin with severe pain also needs urgent in-person assessment; it should not be dismissed as an ordinary injection wheal or assigned a cause without examination.

For skin botox, I use the same aftercare instructions as for other toxin sessions. Stay upright and do not press or massage the area for about four hours, although the evidence that posture alone limits diffusion is thin. Gentle pressure on bleeding points, no rubbing. No exercise, alcohol or heat for about a day. Do not stop a prescribed anticoagulant without the prescriber. I review at about two weeks. New eyelid droop or a change in the smile warrants prompt contact with the treating clinician, while the warning symptoms above require assessment without waiting for that review.

And one firm line: if a cocktail contains toxin, it is injected, never spread over a channelled bed after microneedling or laser.

Frequently asked questions

This article is educational material for medical professionals. It does not replace product labelling, local regulation or clinical judgement.